{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:44:45Z","timestamp":1778687085127,"version":"3.51.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Departmental resources"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mebendazole (MBZ) is an anti-helminthic that has shown antitumor activity in mice with gliomas and subsequently in medulloblastoma models. Safety and tolerability have been demonstrated in adults with brain tumors but not explored in children as a monotherapy. We characterized the safety and maximum tolerated dose of oral MBZ in pediatric patients with refractory or progressive brain tumors and assessed progression-free survival (PFS) as a secondary objective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients up to 21 years of age with refractory or progressive brain tumors were enrolled at 2 centers in a 3\u2005+\u20053 design with 3 doses of MBZ (1250, 1875, or 2500 mg\/m2\/day). MBZ was taken orally 3 times per day and continued until there were signs of toxicity or clinical\/radiographic progression. Safety and tolerability were analyzed with descriptive statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 17 patients enrolled between 2017 and 2022 with diffuse intrinsic pontine gliomas, high-grade astrocytomas, diffuse midline gliomas, glioblastoma multiform, ependymoma, and nonspecific gliomas. At all 3 dose levels, MBZ was well-tolerated with no dose-limiting toxicities. 121 adverse events (AE) including 69 AEs possibly\/probably related to MBZ occurred\u2014the most common being decreased lymphocyte count (n\u2005=\u20056). Six grade 3 (anorexia, dehydration, hypokalemia, increased GGT, blood bilirubin increased, and aspartate aminotransferase increased) and 1 grade 4 (vomiting) were reported. The mean PFS was 7.6 weeks (range of 2 to 24 weeks).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MBZ is safe and tolerable in treating refractory or progressive pediatric brain tumors, with doses up to 2500 mg\/m2\/day. There was limited evidence of single-agent efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/nop\/npaf060","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:50:16Z","timestamp":1749196216000},"page":"1092-1098","source":"Crossref","is-referenced-by-count":3,"title":["Phase 1 study of mebendazole therapy for refractory\/progressive or recurrent pediatric brain tumors"],"prefix":"10.1093","volume":"12","author":[{"given":"Paul","family":"Phan","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie L","family":"Stapleton","sequence":"additional","affiliation":[{"name":"Cancer and Blood Disorders Institute, Johns Hopkins All Children\u2019s Hospital , St. Petersburg, Florida ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J","family":"Riggins","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]},{"name":"Cellular and Molecular Medicine Program, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]},{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A","family":"Koldobskiy","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-7037","authenticated-orcid":false,"given":"Eric","family":"Raabe","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9193-9344","authenticated-orcid":false,"given":"Kenneth J","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"2025122607315936700_CIT0001"},{"issue":"3","key":"2025122607315936700_CIT0002","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11060-016-2202-1","article-title":"Relapse patterns and outcome after relapse in standard risk medulloblastoma: A report from the HIT-SIOP-PNET4 study","volume":"129","author":"Sabel","year":"2016","journal-title":"J Neurooncol."},{"issue":"4","key":"2025122607315936700_CIT0003","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/adc.66.4.532","article-title":"High mebendazole doses in pulmonary and hepatic hydatid disease","volume":"66","author":"Messaritakis","year":"1991","journal-title":"Arch Dis Child."},{"issue":"2","key":"2025122607315936700_CIT0004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1586\/14787210.7.2.145","article-title":"Benzimidazoles for the treatment of cystic and alveolar echinococcosis: what is the consensus?","volume":"7","author":"Vuitton","year":"2009","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"13","key":"2025122607315936700_CIT0005","first-page":"1201","article-title":"The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells1","volume":"1","author":"Sasaki","year":"2002","journal-title":"Mol Cancer Ther."},{"issue":"42","key":"2025122607315936700_CIT0006","doi-asserted-by":"crossref","first-page":"68571","DOI":"10.18632\/oncotarget.11851","article-title":"Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model","volume":"7","author":"Williamson","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2025122607315936700_CIT0007","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijrobp.2018.08.046","article-title":"Mebendazole potentiates radiation therapy in triple-negative breast cancer","volume":"103","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"9","key":"2025122607315936700_CIT0008","first-page":"2963","article-title":"Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo1","volume":"8","author":"Mukhopadhyay","year":"2002","journal-title":"Clin Cancer Res."},{"issue":"8","key":"2025122607315936700_CIT0009","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/1541-7786.MCR-07-2159","article-title":"Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells","volume":"6","author":"Doudican","year":"2008","journal-title":"Mol Cancer Res: MCR"},{"issue":"1","key":"2025122607315936700_CIT0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-2407-10-143","article-title":"Potent inhibition of tumoral hypoxia-inducible factor 1\u03b1 by albendazole","volume":"10","author":"Pourgholami","year":"2010","journal-title":"BMC Cancer"},{"issue":"5","key":"2025122607315936700_CIT0011","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00280-007-0538-0","article-title":"Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice","volume":"61","author":"Martarelli","year":"2008","journal-title":"Cancer Chemother Pharmacol."},{"issue":"3","key":"2025122607315936700_CIT0012","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.4158\/EP10390.CR","article-title":"Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma","volume":"17","author":"Dobrosotskaya","year":"2011","journal-title":"Endocrine Practice"},{"issue":"3","key":"2025122607315936700_CIT0013","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/0284186X.2013.844359","article-title":"Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer","volume":"53","author":"Nygren","year":"2014","journal-title":"Acta Oncologica (Stockholm, Sweden)"},{"issue":"9","key":"2025122607315936700_CIT0014","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/neuonc\/nor077","article-title":"Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme","volume":"13","author":"Bai","year":"2011","journal-title":"Neuro-Oncology."},{"issue":"4","key":"2025122607315936700_CIT0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/neuonc\/nou234","article-title":"Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis","volume":"17","author":"Bai","year":"2015","journal-title":"Neuro-Oncology."},{"issue":"1","key":"2025122607315936700_CIT0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-14-0755-T","article-title":"Repurposing the antihelmintic mebendazole as a hedgehog inhibitor","volume":"14","author":"Larsen","year":"2015","journal-title":"Mol Cancer Ther."},{"issue":"Jun 15","key":"2025122607315936700_CIT0017","doi-asserted-by":"crossref","first-page":"120536","DOI":"10.1016\/j.lfs.2022.120536","article-title":"Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer","volume":"299","author":"Hegazy","year":"2022","journal-title":"Life Sci."},{"issue":"1","key":"2025122607315936700_CIT0018","first-page":"vdaa154","article-title":"Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: Results of a phase 1 clinical trial","volume":"3","author":"Gallia","year":"2021","journal-title":"Neurooncol. Adv.."},{"issue":"4","key":"2025122607315936700_CIT0019","doi-asserted-by":"crossref","first-page":"e30874","DOI":"10.1002\/pbc.30874","article-title":"A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas","volume":"71","author":"Krystal","year":"2024","journal-title":"Pediatric Blood Cancer"},{"issue":"15","key":"2025122607315936700_CIT0020","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-14-2681","article-title":"Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model","volume":"21","author":"Bai","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2025122607315936700_CIT0021","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2119\/molmed.2017.00011","article-title":"Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors","volume":"23","author":"De Witt","year":"2017","journal-title":"Mol Med."},{"issue":"12","key":"2025122607315936700_CIT0022","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s00432-013-1539-5","article-title":"Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer","volume":"139","author":"Nygren","year":"2013","journal-title":"J Cancer Res Clin Oncol."},{"issue":"13","key":"2025122607315936700_CIT0023","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1002\/cam4.3094","article-title":"Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma","volume":"9","author":"Patil","year":"2020","journal-title":"Cancer Med"},{"issue":"May 27","key":"2025122607315936700_CIT0024","doi-asserted-by":"crossref","first-page":"101449","DOI":"10.1016\/j.eclinm.2022.101449","article-title":"Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial.","volume":"49","author":"Patil","year":"2022","journal-title":"eClinicalMedicine"},{"issue":"18","key":"2025122607315936700_CIT0025","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1158\/1078-0432.CCR-22-0803","article-title":"Upfront biology-guided therapy in diffuse intrinsic pontine glioma: Therapeutic, molecular, and biomarker outcomes from PNOC003","volume":"28","author":"Kline","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025122607315936700_CIT0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00412-015-0510-4","article-title":"Histone H3 mutations--a special role for H3.3 in tumorigenesis?","volume":"124","author":"Kallappagoudar","year":"2015","journal-title":"Chromosoma."},{"issue":"2","key":"2025122607315936700_CIT0027","first-page":"153","article-title":"Pediatric high-grade glioma: Biologically and clinically in need of new thinking","volume":"19","author":"Jones","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025122607315936700_CIT0028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11060-014-1448-8","article-title":"Diffuse intrinsic pontine glioma: A reassessment","volume":"119","author":"Robison","year":"2014","journal-title":"J Neurooncol."},{"issue":"2","key":"2025122607315936700_CIT0029","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3390\/ijms24021334","article-title":"Emerging perspectives on the antiparasitic mebendazole as a repurposed drug for the treatment of brain cancers","volume":"24","author":"Meco","year":"2023","journal-title":"Int J Mol Sci."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npaf060\/63449633\/npaf060.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/6\/1092\/63449633\/npaf060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/6\/1092\/63449633\/npaf060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T12:32:08Z","timestamp":1766752328000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/12\/6\/1092\/8158244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,7]]},"published-print":{"date-parts":[[2025,12,26]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npaf060","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,6,7]]}}}